As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors.
Gordon Mills, MD, PhD
Advertisement
Articles by Gordon Mills, MD, PhD
Advertisement
Latest Updated Articles
Homologous Recombination Deficiency and PARP Inhibition in Ovarian CancerPublished: June 6th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
Cognitive Function Improvements Highlighted With Acupuncture Use in Breast Cancer
3
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
4
The Battle Between MARIPOSA and FLAURA2 Regimens in NSCLC
5
